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SObjective: The purpose of this study is to investigate the clinical characteristics, prognosis, and risk factors of
patients in whom cervical lymph node cancer recurred after esophageal cancer surgery with 2-field lymph node
dissection.
Methods: Between 2000 and 2010, 471 consecutive patients who had undergone esophagectomy with 2-field
lymph node dissection for esophageal squamous cell carcinoma were enrolled in this study.
Results:Recurrence was seen in 96 patients. Isolated cervical lymph node recurrence (group A) developed in 21
patients, locoregional recurrence only and without cervical lymph node recurrence (group B) in 29, and distant
recurrence with or without locoregional recurrence (group C) in 46 patients. The median times to recurrence
after surgery in groups A, B, and C were 20, 16, and 12 months, respectively (P ¼ .634). 2- and 5-year rates
of isolated cervical lymph node recurrence were 4.1% and 5.6%, respectively. The median survival times
from diagnosis of recurrence were 13, 7, and 5 months in groups A, B, and C, respectively. The difference in
survival between groups A and C was statistically significant (P ¼ .030). Upper thoracic esophageal cancer
and positive recurrent laryngeal node at the time of initial surgery were independent risk factors for cervical
recurrence-free survival as determined by univariate and multivariate analysis.
Conclusions: This study shows that 2-field lymph node dissection can be performedwith an acceptable rate of cer-
vical lymph node recurrence. Patients with isolated cervical lymph node recurrence demonstrated longer survival
fromdiagnosis of recurrence thanpatientswith other sites of recurrence. (JThoracCardiovascSurg2013;146:365-71)The prognosis of patients with esophageal carcinoma has
been historically dismal and the operative mortality for
esophagectomy was relatively high at approximately 30%
before the 1980s.1 More recently, it has been reported that
operative mortality has decreased to less than 5% in high-
volume medical centers.2 Despite the improvements in the
various treatment methods,3 long-term patient survival is
still unsatisfactory inasmuch as recurrent disease develops
in large numbers of patients after curative esophagectomy.
Lymph node recurrence in the cervical, mediastinal, and
abdominal regions is widely recognized as one of the
most important prognostic factors.4-6 However, a cervical
lymph node recurrence has the chance for a complete cure
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The Journal of Thoracic and Cawith recurrence at other sites.7 Some surgeons have used ex-
tended esophagectomy with 3-field lymph node dissection
to improve long-term surgical outcomes.8,9 On the other
hand, other surgeons have suggested that extended nodal
dissection has little or no survival benefit and, in fact,
a relative higher morbidity.10,11 Therefore, the role of the
optimal extent of lymph node dissection during
esophagectomy has not yet been established.
Our institution has mainly performed esophagectomy
with 2-field (mediastinal and abdominal lymph node)
lymph node dissection; thus cervical lymph node dissection
was not performed in all patients of this study. The objec-
tives of the present study are to investigate the clinical char-
acteristics and the prognosis of patients in whom cervical
lymph node cancer recurred after curative esophagectomy
with 2-field lymph node dissection for esophageal squa-
mous cell carcinoma.PATIENTS AND METHODS
The Institutional Review Board of Asan Medical Center, University of
Ulsan College of Medicine, in the Republic of Korea, approved this study.
Patient Population
Retrospective analysis was performed using a prospectively collected
database of patients who underwent esophageal resection and reconstruc-
tion for the period from January 2000 to December 2010 at Asan Medical
Center, Seoul, Korea. Six hundred sixty-six patients with esophagealrdiovascular Surgery c Volume 146, Number 2 365
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Scancer underwent surgical resection. This study included any patients (1)
who had a histologic diagnosis of esophageal squamous cell carcinoma,
(2) who underwent esophagectomy with R0 resection, and (3) who under-
went 2-field lymph node dissection. It excluded any patients who had
hypopharyngeal cancer or cervical esophageal cancer, which are located
above 20 cm from the upper incisors by endoscopic measurements. Four
hundred seventy-one consecutive patients who met these inclusion and
exclusion criteria were enrolled in the present study.
Our study included 439 (93.2%)men and 32 (6.8%) womenwith amean
age of 62.6 years (range, 38-94 years). Themedian follow-up period was 35
months (range, 1-132)months. Therewere 12 (2.5%) deaths within 30 days
after surgery. The causes of death were postoperative pneumoniawith acute
respiratory failure in 9 patients, empyemawith septic shock in 1, acute renal
failure with multiorgan failure in 1, and deep vein thrombosis with hepatic
failure in 1. Vocal cord palsy occurred in 36 (7.6%) patients: the left vocal
cord in 27; the right vocal cord in 6, and bilaterally in 3.
Surgical Procedures
The operations were performed by 2 surgeons. The Ivor Lewis operation
(median laparotomy and right transthoracic esophagectomy with recon-
struction) and the McKeown operation (right thoracotomy, median laparot-
omy, and left cervical esophagectomy with reconstruction) are the usual
procedures used for esophagectomy at our institution. Cervical esophagec-
tomy with reconstruction is usually performed when the proximal tumor
margin is located above 25 cm from upper incisor, as determined by esoph-
agogastroscopic evaluation. A method of anastomosis, including manual
anastomosis, circular stapler anastomosis, or semimechanical anastomosis
with a linear stapler, was decided according to the surgeon’s preference or
the patient’s characteristics. The definition of our 2-field lymph node
dissection was resection of the mediastinal and abdominal lymph node sta-
tions. A meticulous dissection of upper, middle, and lower paraesophageal,
subcarinal, upper and lower paratracheal, and a right and left pulmonary
hilar lymph node was followed by thoracic esophageal resection. The right
recurrent laryngeal nerve chain was fully dissected during mediastinal
lymph node dissection, but the left recurrent laryngeal nerve chain was
not routinely dissected. The abdominal lymph nodes were dissected,
including paracardiac nodes, nodes along the perigastric lesser curvature,
left gastric artery nodes, celiac axis nodes, and common hepatic artery
nodes, through median laparotomy.
TNM Staging, Neoadjuvant Therapy, and Follow-up
In our study, the clinical staging was based on the sixth American Joint
Committee on Cancer (AJCC) TNM classification,12 because it was nearly
impossible to determine the clinical stage, according to the seventh AJCC
TNM classification, without pathologic confirmation of lymph nodes
during the retrospective review of preoperative evaluations. However, the
pathologic staging was based on the revised seventh AJCC TNM classifi-
cation.13 One hundred ninety-four (41.2%) patients of 471 study popula-
tion received protocol-based neoadjuvant chemoradiation before curative
esophagectomy. The protocol-based treatment plan for patients with
esophageal cancer at our institution, which has been followed since
1993, has been described previously14-16 and meant that the incidence of
neoadjuvant therapy was higher than that seen in other studies.
Neoadjuvant therapy was administered (1) when the patients had
a greater than T2 or N1 stage in preoperative clinical evaluations,
(2) when the patient’s age was less than 75 years, (3) when the patient366 The Journal of Thoracic and Cardiovascular Surgwas otherwise medically well without significant other diseases, and (4)
when the patient consented to neoadjuvant treatment. Surgery was
performed within 4 to 8 weeks from the end of the neoadjuvant
treatment. We performed immediate operation when patients had clinical
T1 and N0 stage or when patients could not receive neoadjuvant
treatment. Therefore, the pathologic staging after neoadjuvant therapy
and followed by esophagectomy may not reflect the true extent of
disease seen before treatment. In other words, there may be strict
differences between pT1 and ypT1 despite the same anatomic extent of
disease at the time of each respective pathologic examination. However,
in this study the pathologic staging was described without the distinction
of receiving or not receiving neoadjuvant therapy.
Postoperative follow-up was conducted at the attending surgeons’, med-
ical, and radiation oncologists’ outpatient clinics. All patients were fol-
lowed up at 3-month intervals for the first year and at 6-month intervals
thereafter. Simple chest radiography and chest and upper abdominal com-
puted tomography (CT) were performed at every follow-up period, and an
esophagogastroscopy and positron emission tomography CT were per-
formed annually or more frequently if any recurrence was suspected.
More specific investigations, such as whole-body bone scintigraphy, brain
CT, or magnetic resonance imaging, were sometimes performed on the
basis of a patient’s suggestive symptoms, physical examination, or
biochemical markers.
Definition of Recurrence
Locoregional recurrence was defined as a recurrence that developed at
the site of previous esophagectomy or as lymph nodes in the cervical,
mediastinal, or upper abdominal area. Distant recurrence was defined as
that occurring in a solid organ through hematogenous spread. Combined
recurrence was defined as both locoregional and distant recurrence found
within 30 days. Diagnosis of recurrent disease was based on histologic
evaluation or definite radiologic findings. We divided the patients with
recurrence into 3 groups to investigate the pattern of cervical lymph
node recurrence and survival: group A, recurrence was detected only in
the cervical lymph nodes; group B, recurrence occurred in a locoregional
area and without cervical lymph node recurrence; and group C, distant
recurrence was observed with or without locoregional recurrence.
We then compared the times to recurrence after the surgery and survival
times after the recurrence in the 3 groups. The risk factors associated with
recurrence-free survival of patients with cervical recurrence (group A) and
the survival times after the treatments for the cervical recurrence (group A)
were also evaluated.
Statistical Analysis
Statistical evaluation was performed using the Statistical Package for
the Social Sciences (SPSS) program version 19.0 for Windows (SPSS,
Inc, Chicago, Ill). Continuous variables were analyzed using the Student
t test (Mann-Whitney U test) or 1-way analysis of variance (Kruskal-
Wallis), and discrete variables were analyzed using the Pearson c2 test
(Fisher’s exact test). Survival after recurrences was defined as the duration
from recurrence to a patient’s death from any cause or last follow-up. Risk
factors associated with recurrence-free survival of patient with cervical
recurrence (group A) were evaluated by univariate analysis considering
age, gender, neoadjuvant therapy, tumor location, clinical T and N stage,
pathologic T and N stage, histologic grade of tumor, and involvement of
recurrent laryngeal lymph nodes. Recurrence rates and survivals were
derived using the Kaplan-Meier method, and the differences between sub-
groups were assessed using the log–rank test. The Cox regression model
was used for multivariate analysis to determine independent risk factors.
RESULTS
The demographic, operative, distribution of recurrences,
clinical, and pathologic data of our study population areery c August 2013
TABLE 1. Demographic and operative data of our study population
Variable All patients (n ¼ 471) Group A (n ¼ 21) Group B (n ¼ 29) Group C (n ¼ 46) P value
Age, y (mean  SD) 62.6  7.8 61.2  8.2 63.5  5.7 64.1  7.3 .382
Gender (%) .220
Male 439 (93.2) 20 (95.2) 27 (93.1) 46 (100)
Tumor location (%) .099
Upper thoracic 36 (7.6) 5 (23.8) 4 (13.8) 2 (4.3)
Middle thoracic 258 (54.8) 12 (57.1) 13 (44.8) 24 (52.2)
Lower thoracic 177 (37.6) 4 (19.0) 12 (41.4) 20 (43.5)
Neoadjuvant therapy (%) .305
Yes 194 (41.2) 8 (38.1) 7 (24.1) 19 (41.3)
No 277 (58.8) 13 (61.9) 22 (75.9) 27 (58.7)
Surgery (%) .337
Ivor Lewis 389 (82.6) 14 (66.7) 23 (79.3) 38 (82.6)
Mckeown 82 (17.4) 7 (33.3) 6 (20.7) 8 (17.4)
No. of dissected lymph nodes, mean (range) 41.2 (6-111) 45.1 (19-111) 42.9 (11-101) 46.4 (11-87) .520
No. of positive lymph nodes, mean (range) 0.87 (0-27) 2.43 (0-18) 2.00 (0-22) 1.93 (0-8) .569
Site of locoregional recurrence
Anastomotic site — 11 3
Mediastinal lymph node — 16 4
Abdominal lymph node — 2 —
Cervical lymph node 21 — 4
Site of distant recurrence
Lung — — 28
Liver — — 12
Bone — — 9
Pleura — — 3
Skin and soft tissue — — 4
Peritoneum — — 4
Brain — — 1
Kidney — — 1
Group A, Patients with recurrence in isolated cervical lymph nodes; Group B, patients with recurrence in a locoregional area and without cervical lymph node recurrence; Group
C, patients with distant recurrence and with or without locoregional recurrence; SD, standard deviation.
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patients who received neoadjuvant therapy and who
underwent surgery alone are shown in Table 3. The median
survival time for all patients was 93 months (95% confi-
dence interval [CI], 70.3-115.6).
Ninety-six of the 471 patients in the study population
had recurrent disease after surgery during the follow-up
period. Fifty patients had locoregional recurrence, 35
had distant recurrence, and 11 had combined recurrence.
Twenty-one recurrences were localized only in the
cervical lymph node (group A), 29 recurrences occurred
in a locoregional site without cervical lymph node
recurrence (group B), and 46 recurrences developed in
a distant site with or without locoregional recurrence
(group C).
Themedian times to recurrence after surgery in groups A,
B, and C were 20 months (95% CI, 17.8-22.2 months), 16
months (95% CI, 12.9-19.1 months), and 12 months (95%
CI, 9.8-14.2 months), respectively (P ¼ .634, log–rank).
Seventy-two of 96 patients with recurrence had recurrence
within 2 years. Two-, 5-, and 10-year rates of isolated cervi-
cal lymph node recurrence were 4.1%, 5.6%, and 7.3%,The Journal of Thoracic and Carespectively. The median survival times after the recurrence
were 13 months (95% CI, 5.1-21.0 months) in group A, 7
months (95% CI, 3.6-10.4 months) in group B, and 5
months (95% CI, 4.5-9.5 months) in group C. There was
statistical difference between groups A and C (P ¼ .030)
(Figure 1).
Risk factors influencing the recurrence of cervical
lymph nodes are analyzed in Table 4. Independent risk
factors associated with recurrence-free survival of group
A in our study patients, and as assessed by univariate
and multivariate analysis, were that the tumor was located
in the upper thoracic esophagus (P ¼ .019) and that lymph
node metastasis was involved in the recurrent laryngeal
lymph node seen at the time of the initial operation
(P ¼ .008).
Twelve (57%) of 21 patients (group A) had isolated
cervical lymph node recurrences in the left side of the
neck. The supraclavicular lymph nodes were the most
common site of recurrent cervical lymph node disease (16
[76.2%] of 21 patients). Single cervical node metastasis
developed in 7 patients and multiple cervical node metasta-
ses in 14.rdiovascular Surgery c Volume 146, Number 2 367
TABLE 2. Clinical and pathologic data of our study population
Variable All patients (n ¼ 471) Group A (n ¼ 21) Group B (n ¼ 29) Group C (n ¼ 46) P value
Clinical T stage (%)* .309
Tx 23 (4.9) 1 (4.8) 3 (10.3) 4 (8.7)
Tis 7 (1.5) 0 (0) 1 (3.4) 0 (0)
T1 228 (48.4) 10 (47.6) 7 (24.1) 12 (26.1)
T2 93 (19.7) 3 (14.3) 11 (37.9) 9 (19.6)
T3 113 (24.0) 7 (33.3) 7 (24.1) 19 (41.3)
T4 7 (1.5) 0 (0) 0 (0) 2 (4.3)
Clinical N stage (%)* .150
N0 301 (63.9) 16 (76.2) 19 (65.5) 24 (52.2)
N1 170 (36.1) 5 (23.8) 10 (34.5) 22 (47.8)
Clinical M stage (%)* .194
M0 456 (96.8) 21 (100) 28 (96.6) 43 (93.5)
M1a 5 (1.1) 0 (0) 0 (0) 0 (0)
M1b 6 (1.3) 0 (0) 1 (3.4) 0 (0)
Mx 4 (0.8) 0 (0) 0 (0) 3 (6.5)
Pathologic T stage (%)y .209
T0 118 (25.1) 1 (4.8) 4 (13.8) 8 (17.4)
Tis 17 (3.6) 0 (0) 0 (0) 0 (0)
T1 212 (45.0) 14 (66.7) 11 (37.9) 12 (26.1)
T2 55 (11.7) 4 (19.0) 5 (17.2) 4 (8.7)
T3 66 (14.0) 2 (9.5) 8 (27.6) 20 (43.5)
T4a 3 (0.6) 0 (0) 1 (3.4) 2 (4.3)
Pathologic N stage (%)y .759
N0 330 (70.1) 10 (47.6) 17 (58.6) 20 (43.5)
N1 93 (19.7) 6 (28.6) 5 (17.2) 12 (26.1)
N2 36 (7.6) 2 (9.5) 5 (17.2) 11 (23.9)
N3 12 (2.5) 3 (14.3) 2 (6.9) 3 (6.5)
Pathologic M stage (%)y .577
M0 468 (99.4) 21 (100) 29 (100) 45 (97.8)
M1 3 (0.6) 0 (0) 0 (0) 1 (2.2)
Histologic grade (%) .385
0 135 (28.7) 1 (4.8) 4 (13.8) 8 (17.4)
Gx 26 (5.5) 3 (14.3) 0 (0) 3 (6.5)
G1 45 (9.6) 3 (14.3) 5 (17.2) 3 (6.5)
G2 229 (48.6) 11 (52.4) 18 (62.1) 27 (58.7)
G3 36 (7.6) 3 (14.3) 2 (6.9) 5 (10.9)
Metastatic lymph node <.001
None 330 (70.1) 10 (47.6) 17 (58.6) 20 (43.5)
Positive lymph node without RLN 114 (24.2) 3 (14.3) 9 (31.0) 25 (54.3)
Positive lymph node with RLN 27 (5.7) 8 (38.1) 3 (10.3) 1 (2.2)
Group A, Patients with recurrence in isolated cervical lymph nodes; Group B, patients with recurrence in a locoregional area and without cervical lymph node recurrence;
Group C, patients with distant recurrence and with or without locoregional recurrence; RLN, recurrent laryngeal lymph node. *Clinical stage based on sixth American Joint
Committee on Cancer TNM stage.12 yPathologic stage based on seventh American Joint Committee on Cancer TNM stage.13
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currence (group A), 2 (9.5%) refused further treatment, 6
(28.6%) received chemotherapy only, 1 (4.8%) received
radiotherapy only, 9 (42.9%) received concurrent chemora-
diation therapy, and 3 (14.3%) underwent surgical neck
dissection.
Fifteen of the 21 patients died during the follow-up
period. Therewere 2 deaths in patients without further treat-
ment (0 and 6 months after recurrence), 4 in those with che-
motherapy (1, 3, 6, and 16 months), 7 in those with
concurrent chemoradiation therapy (9, 10, 12, 13, 18, 21,368 The Journal of Thoracic and Cardiovascular Surgand 28 months), and 2 in those with surgical neck dissection
(4 and 35 months).
Six of the 21 patients were alive during the follow-up
period, 2 patients with chemotherapy (at 0 and 86 months
from recurrence to last follow-up), 1 with radiotherapy (56
months), 2 with concurrent chemoradiation therapy (5 and
7 months), and 1 with surgical neck dissection (33 months).
DISCUSSION
Many different therapeutic options have been attempted
to reduce the rate of recurrent disease and to increase theery c August 2013
TABLE 3. Clinical characteristics of patients who underwent surgery
alone (n¼ 277) and neoadjuvant therapy followed by surgery (n¼ 194)
Variables
Surgery alone
(n ¼ 277)
Neoadjuvant
therapy
(n ¼ 194)
P
value
Clinical T stage (%)* <.001z
cTx, cTis, cT1 219 (79.1) 39 (20.1)
cT2-4 58 (20.9) 155 (79.9)
Clinical N stage (%)* <.001z
cN0 241 (87.0) 60 (30.9)
cN1 36 (13.0) 134 (69.1)
Pathologic T stage (%)y .293
pT0, pTis, pT1 201 (72.6) 146 (75.3)
pT2-4 76 (27.4) 48 (24.7)
Pathologic N stage (%)y .217
pN0 189 (68.2) 141 (72.7)
pN1-3 88 (31.8) 53 (27.3)
Recurrence at any site (%) .204
Yes 62 (22.4) 34 (17.5)
No 215 (77.6) 160 (82.5)
Recurrence-free survival (%) .914
2-y 82.5 83.7
5-y 75.7 79.2
Overall survival (%) <.001z
2-y 81.7 66.7
5-y 63.7 50.2
*Clinical stage based on sixth American Joint Committee on Cancer TNM stage.12
yPathologic stage based on seventh American Joint Committee on Cancer TNM
stage.13 zP value< .05
FIGURE 1. Overall survival curve from the date of the recurrence to the
date of death or last follow-up in groups A, B and C by using a Kaplan-
Meier estimate.
TABLE 4. Univariate and multivariate analysis for recurrence-free
survival in patients with cervival lymph node recurrence (group A)
by using the Kaplan-Meier method and Cox regression model
Variables
Analysis
Univariate
P value
Multivariate
HR 95% CI P value
Age .196
Gender .593
Neoadjuvant therapy .793
Clinical T stagey .697
Clinical N stagey .490
Tumor location .006* 2.422 1.159-5.061 .019*
Pathologic T stagez .248
Pathologic N stagez <.001* 1.169 0.570-2.397 .670
Histologic grade .295
RLN metastasis <.001* 2.839 1.311-6.148 .008*
HR, Hazard ratio; CI, confidence interval; RLN, recurrent laryngeal lymph node.
*P value< .05. yClinical stage based on sixth American Joint Committee on Cancer
TNM stage.12 zPathologic stage based on seventh American Joint Committee on
Cancer TNM stage.13
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worldwide.
Radical esophagectomy with 3-field lymph node dissec-
tion (cervical, mediastinal, and abdominal lymph nodes)
has been performed by some surgeons, especially Japanese
groups.8,9 Several studies also suggested that extended
lymphadenectomy containing a cervical lymph node
dissection may prevent recurrent disease and improve the
long-term outcomes.17,18 However, other authors have
reported that extended nodal dissection did not contribute
to reduced recurrence rates or to increased long-term sur-
vival outcomes.4,5,10,11,19-21 We found that the 2-, 5-, and
10-year rates of isolated cervical lymph node recurrence
were 4.1%, 5.6%, and 7.3%, respectively, by using the
Kaplan-Meier estimate in this study.
Yano and colleagues6 suggested that patients with cervi-
cal lymph node recurrence still have the chance of cure, al-
though the prognosis is poor. Motoyama and associates7
reported that the survival after recurrence in patients with
cervical recurrence was significantly longer than in patients
with other recurrences. At the present study, the median
time to recurrence after surgery was longer in group A
than in groups B and C, although there was no statistical dif-
ference. Survival after recurrence in group A was signifi-
cantly longer than that of group C, although there was no
statistical difference between groups A and B.The Journal of Thoracic and CaAs shown in the present study, upper thoracic esophageal
carcinoma and metastasis of recurrence in laryngeal lymph
nodes at the time of surgery were independent risk factors
for recurrence-free survival of patients with cervical lymph
nodal recurrence (group A). It is often suggested that the
prognosis of upper thoracic esophageal cancer is poorer
than that ofmiddle or lower thoracic esophageal cancer.22 Ta-
bira and colleagues23 suggested that recurrent laryngeal node
involvement was a significant factor associated with cervical
node metastasis at the time of surgery, although they did notrdiovascular Surgery c Volume 146, Number 2 369
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surgery in their study group. Shim, Kim, and Kim21 reported
that recurrent laryngeal lymph node metastasis was 35% in
their 2-field group and that the rates of recurrent laryngeal
lymph node metastasis and cervical lymph node metastasis
were 37% and 19%, respectively, in their 3-field group.
However, there was no significant difference in cervical
lymph node recurrence after surgery in either group.
In this study, neoadjuvant therapy was administered in
nearly half the patients comprising the study population.
The overall survival of patients with surgery alone was
statistically better than that of patients with neoadjuvant
therapy, but there were no statistical differences in the re-
currence rate and recurrence-free survival after surgery be-
tween the 2 groups. However, these results do not mean that
the treatment value of neoadjuvant therapy is worse than the
value of surgery alone, because patients with advanced clin-
ical stage were more likely to be in the neoadjuvant group.
Dresner and Griffin4 indicated that metastasis of cervical
lymph nodes at the time of surgery may not be associated
with clinical recurrence and that it may already be a mani-
festation of systemic disease. Nakagawa and colleagues24
suggested that these patients may already have micrometa-
static disease beyond the area of extended lymphadenec-
tomy at the time surgery. Meguid and associates25 insisted
that neoadjuvant treatment is critical in preventing recurrent
disease and that it may also eliminate distant disease or mi-
crometastasis outside of the local surgical or radiation field.
For these reasons, they suggested that surgery alone con-
taining nodal clearance, regardless of the extent of nodal
dissection, is considered only as a local control. They also
emphasized that recurrence and long-term survival are
probably related not only by the extent of surgical proce-
dure, but also by neoadjuvant or adjuvant modalities and
various biologic and histologic tumor-related factors.
Study Limitations
The present study has several limitations. First, this study
was a retrospective analysis. Second, a comparison between
2-field and 3-field lymph node dissection could not be per-
formed. Third, the statistical power for the survival and
risk factor analyses may be weak inasmuch as the number
of subgroups was relatively small. Fourth, cancer recurrence
rate must be reported in a time-related manner, inasmuch as
a recurrence is considered to be a time-related diagnosis. Un-
fortunately, we were not able to compare our results with
other reports, because few reports have described the cervical
lymph node recurrence rate in a time-related manner. As the
efficacy of radical extended nodal dissection remains contro-
versial, it is important to directly compare the outcomes of
2-field and 3-field lymph node dissection, and it is crucial
that prospective, randomized, controlled trials be conducted
to determine the most effective modalities for improving the
therapeutic outcomes for patients with esophageal cancer.370 The Journal of Thoracic and Cardiovascular SurgCONCLUSIONS
We found that the 2-, 5-, and 10-year rates of isolated cer-
vical lymph node recurrence were 4.1%, 5.6%, and 7.3%,
respectively, in patients who had undergone 2-field lymph
node dissection. The survival of patients with isolated cer-
vical lymph node recurrence was relatively better than
that of patients with recurrence at other sites. This shows
that 2-field lymph node dissection can be performed with
an acceptable rate of cervical recurrence. Independent risk
factors for recurrence-free survival of patients with cervical
recurrence were a tumor located in the upper thoracic
esophagus and metastasis of a recurrent laryngeal lymph
node that already existed at the time of surgery.References
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